Email this article 
Chronobiological approach to the treatment of patients with benign prostate hyperplasia and chronic prostatitis: results of a morphological examination
- Authors: Kuzmenko A.V.1, Gyaurgiev T.A.1, Barannikov I.I.1, Leybovich B.E.2
-
Affiliations:
- Burdenko Voronezh State Medical University
- Private Healthcare Institution "Clinical Hospital "Russian Railways-Medicine" of the city of Voronezh"
- Issue: Vol 11, No 2 (2021)
- Pages: 113-122
- Section: Original articles
- URL: https://journals.eco-vector.com/uroved/article/view/56807
- DOI: https://doi.org/10.17816/uroved56807
- ID: 56807
Cite item
Open Access
Access granted
Abstract
MATERIALS AND METHODS: 60 patients with benign prostatic hyperplasia (BPH) and category II chronic prostatitis (NIH, 1995) were examined. The average age of the patients was 60.5 ± 5.5 years. The patients were divided into two groups of 30 people each. The comparison group (GC) included patients who received standard therapy with drugs from the group of alpha-blockers and fluoroquinolones. The main group (MG) consisted of patients who received standard therapy in combination with physiotherapy sessions with the device “SMART-PROST”, which were carried out in the acrophase of the chronorhythm. After the end of the course of therapy all patients underwent transurethral resection of the prostate, after which a morphological and morphometric (immunohistochemical) study of the obtained material was carried out.
RESULTS: According to the results of the morphological and morphometric examination of the histological material in patients of the CG and MG, statistically significant differences were revealed in all the studied parameters, which testify to the persistence of signs of the inflammatory process in the CG, while in the MG, the severity of inflammation was significantly lower.
CONCLUSION: According to the results of the study, personalized complex therapy of patients with benign prostatic hyperplasia in combination with chronic prostatitis using a combined physiotherapeutic effect of the SMART-PROST device, taking into account the individual chronobiological characteristics of patients, allows to more effectively arrest the inflammatory process in the prostate tissue, which can lead to a decrease in the number of postoperative complications. However, the last statement requires further more detailed study.
Full Text
About the authors
Andrey V. Kuzmenko
Burdenko Voronezh State Medical University
Author for correspondence.
Email: kuzmenkoav09@yandex.ru
SPIN-code: 6981-7490
Scopus Author ID: 7003998310
http://vrngmu.ru/academy/personnel/978/
Dr. Sci. (Med), Professor, Head of the Urology Department
Russian Federation, 10, Studencheskaya str., Voronezh, 394036Timur A. Gyaurgiev
Burdenko Voronezh State Medical University
Email: tima001100@mail.ru
ORCID iD: 0000-0002-6261-3641
SPIN-code: 8050-7190
Cand. Sci. (Med), Associate Professor of the Urology Department
Russian Federation, 10, Studencheskaya str., Voronezh, 394036Ivan I. Barannikov
Burdenko Voronezh State Medical University
Email: vanchyck@yandex.ru
Postgraduate student, Urology Department
Russian Federation, 10, Studencheskaya str., Voronezh, 394036Boris E. Leybovich
Private Healthcare Institution "Clinical Hospital "Russian Railways-Medicine" of the city of Voronezh"
Email: bel.46@mail.ru
ORCID iD: 0000-0001-6673-1859
SPIN-code: 4206-4245
Head of thePathological Department of the Stationary Unit No. 1 at the Voronezh-1 Station
Russian Federation, 2, Zdorovye lane,Voronezh, 394036References
- Alyaev YuG, Glybochko PV, Pushkar’ DYu [editors]. Urologiya. Rossiiskie klinicheskie rekomendatsii. Moscow: GEOTAR-Media, 2018. 480 p. (In Russ.)
- Gravas S, Cornu JN, Gacci M, et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS) [Internet]. EAUGuideline. 2020 [cited 01.06.2021]. Available from: https: // uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.
- Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. Campbell-Walsh. Urology, 10th edition. 2012. P. 2570–2610. doi: 10.1016/B978-1-4160-6911-9.00091-8
- Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. Combination drug therapy in patients with BPH. Urologiia. 2018;(1):101–105. (In Russ.) doi: 10.18565/urology.2018.1.101-105
- Schaeffer AJ. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis. Urology. 2002;60(6):5–6. doi: 10.1016/s0090-4295(02)02292-6
- Nickel J. Prostatitis. CUA Guidelines. Can Urol Assoc J. 2011;5(5):306–315. doi: 10.5489/cuaj.11211
- Rees J, Abrahams M, Doble A, Cooper A. Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509–525. doi: 10.1111/bju.13101
- Kudryavcev YuV, Sivkov AV. Morphological alteration in benign prostatic hyperplasia tissue. Experimental & clinical urology. 2010;(1):18–22. (In Russ.)
- Bartoletti R, Cai T, Mondaini N, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol. 2007;178(6):2411–2415. doi: 10.1016/j.juro.2007.08.046
- Huang XH, Qin B, Liang YW. LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate. Zhonghua Nan KeXue. 2013;19(1):35–39. (In Chinese).
- Krsmanovic A, Tripp D, Nickel J, et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J. 2014;8(11–12):403–408. doi: 10.5489/cuaj.2179
- Asgari SA, Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention. Int J Prev Med. 2011;2(1):28–31.
- Logvinov LA. Kliniko-morfologicheskie kharakteristiki khronicheskogo prostatita [dissertation]. Moscow, 2008. (In Russ.)
- Vaupel P, Kelleher DK. Blood flow and oxygenation status of prostate cancers. Adv Exp Med Biol. 2013;765:299–305. doi: 10.1007/978-1-4614-4989-8_42
- Mustafaev AT, Kyzlasov PS, Dianov MP, et al. Surgical treatment of benign prostatic hyperplasia: the past and the present. Urologicheskie vedomosti. 2019;9(1):47–56. (In Russ.) doi: 10.17816/uroved9147-56
- Al’-Shukri SKh, Tkachuk VN, Gorbachev AG, et al. Urodinamicheskie issledovaniya v diagnostike infravezikal’noi obstruktsii u muzhchin. Urologiya i nefrologiya. 1998;(6):27–29. (In Russ.)
- Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. The efficacy of fesoterodine in patients after transurethral resection of the prostate. Urologiia. 2019;(1):52–55. (In Russ.) doi: 10.18565/urology.2019.1.52-55
- Martov AG, Merinov DS, Kornienko SI, et al. Posleoperatsionnye urologicheskie oslozhneniya transuretral’nykh ehlektrokhirurgicheskikh vmeshatel’stv na predstatel’noi zheleze po povodu adenomy. Urologiia. 2006;(2):25–31. (In Russ.)
- Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA, Barannikov II. Chronobiological status of patients with chronic prostatitis and prostate adenoma. System analysis and management in biomedical systems. 2017;16(3):513–516. (In Russ.)
- Lanina VA, Khimicheva MN, Kuz’menko VV, et al. Khronobiologicheskie osobennosti bol’nykh s khronicheskim prostatitom pri adenome prostaty. Tendentsii razvitiya nauki i obrazovaniya. 2020;(66–1):111–114. (In Russ.)
- Barannikov II, Kuzmenko AV, Gyaurgiev TA, Kuzmenko VV. Evaluation of the effectiveness of personalized complex therapy in patients with benign prostatic hyperplasia and chronic prostatitis. Urology reports (St. Petersburg). 2021;11(1):39–48. (In Russ.) doi: 10.17816/uroved56773
- Al-Shukri SKh, Gorbachev AG, Borovets SYu, et al. Prostatilen treatment of prostatic adenoma. Urologiia. 2006;(6):22–25. (In Russ.)
- Bokov AI, Zabelin MV, Kyzlasov PS. Efficiency of physiotherapy treatment of chronic bacterial prostatitis. Urologicheskie vedomosti. 2016;6(1):10–15. (In Russ.) doi: 10.17816/uroved6110-15.
Supplementary files
